Immatics (NASDAQ:IMTX) Shares Sold by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC cut its stake in Immatics (NASDAQ:IMTX) by 27.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,155 shares of the company’s stock after selling 4,956 shares during the period. Exchange Traded Concepts LLC’s holdings in Immatics were worth $150,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Goldman Sachs Group Inc. lifted its holdings in shares of Immatics by 324.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,548,909 shares of the company’s stock valued at $16,310,000 after purchasing an additional 1,183,860 shares during the last quarter. Wasatch Advisors LP purchased a new stake in Immatics in the first quarter valued at approximately $7,676,000. Nan Fung Group Holdings Ltd acquired a new stake in shares of Immatics in the first quarter valued at approximately $165,000. Affinity Asset Advisors LLC grew its position in shares of Immatics by 75.0% during the first quarter. Affinity Asset Advisors LLC now owns 350,000 shares of the company’s stock worth $3,678,000 after acquiring an additional 150,000 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Immatics by 38.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,225,360 shares of the company’s stock worth $33,899,000 after acquiring an additional 891,191 shares during the last quarter. Institutional investors and hedge funds own 64.41% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on IMTX shares. Piper Sandler began coverage on shares of Immatics in a research note on Monday, October 7th. They set an “overweight” rating and a $19.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immatics in a report on Thursday, September 5th.

Immatics Trading Down 0.8 %

Shares of IMTX stock opened at $9.54 on Wednesday. The company has a market capitalization of $807.64 million, a P/E ratio of -9.00 and a beta of 0.75. The business’s 50 day moving average is $11.16 and its two-hundred day moving average is $11.43. Immatics has a twelve month low of $7.15 and a twelve month high of $13.77.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.17. The firm had revenue of $20.19 million for the quarter, compared to analyst estimates of $12.36 million. Immatics had a negative net margin of 103.99% and a negative return on equity of 23.34%. As a group, equities analysts predict that Immatics will post -0.94 earnings per share for the current fiscal year.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.